Short Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Grows By 10.9%

Benitec Biopharma Inc. (NASDAQ:BNTC) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 12,200 shares, a growth of 10.9% from the March 31st total of 11,000 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average trading volume of 79,100 shares, the short-interest ratio is presently 0.2 days.

Benitec Biopharma Trading Up 7.7 %

NASDAQ BNTC traded up $0.53 on Monday, reaching $7.43. The company had a trading volume of 26,843 shares, compared to its average volume of 65,968. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.62 and a quick ratio of 3.62. Benitec Biopharma has a 1-year low of $1.86 and a 1-year high of $9.01. The company’s fifty day moving average is $5.23 and its 200-day moving average is $3.93.

Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings data on Tuesday, February 13th. The biotechnology company reported ($2.64) EPS for the quarter.

Hedge Funds Weigh In On Benitec Biopharma

An institutional investor recently bought a new position in Benitec Biopharma stock. Adage Capital Partners GP L.L.C. acquired a new position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 189,188 shares of the biotechnology company’s stock, valued at approximately $572,000. Adage Capital Partners GP L.L.C. owned 7.42% of Benitec Biopharma as of its most recent SEC filing. 52.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, JMP Securities upped their target price on shares of Benitec Biopharma from $10.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Monday, April 22nd.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.